1Janetzki S, Palla D, Rosenhauer V, et al. Immunization of cancer patients with autologous cancer-derived heat shock protein gp96 preparations:A pilot study. Int J Cancer, 2000, 88 : 232-238.
2Kugler A, Stuhler G, Walden P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic call hybrids. Nat Med, 2000, 21 : 332-336.
3Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptideor tumor lasate-pulsed dendritic cells. Nat Med, 1998, 19:328-332.
4Pramod K, Srivastava. Purification of hMat shock protein-peptide complex for use in vaccination against cancers and intracellular pathogens. Methods, 1997, 12:165-171.
5Mayordomo JL, Zorina T, Storkus W, et al. Bone marrow-derived dendritie eeUs serve as potent adjuvants for peptide-based antitumor vaccines. Stem Cells, 1997,15:94-103.
6Blachere NE, Li ZH, Chandawarkar RY, et al. Heat shock protein-peptide eomplexs, reconstituted in vitro, elicit peptide-specific cytotoxic T lymphocyte response and tumor immunity. J Exp Med, 1997, 186 : 1315-1322.
7Yasuaki T, Ping P,, Kang L, et al. Immunotherapy of tumor with autologous tumor-derived heat shock protein preparations. Science, 1997,278:117-120.
8Mellman I, Steitunan R. Dendritic cells: specialized and regulated antigen processing machine. J Cell, 2001, 106: 255-258.
9Chiodoni C, Paglia P, Stoppacciaro A, et al. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor( GM-CSF)and CIMO ligand genes take up and present endugenuus tumor-associated antigens, and prim naive mice for a cytotoxic T lymphocyte response. J Exp Med, 1999, 190: 125-133.
10Dallal R, Christakos P, kee K, et al. Paucity of dendritic cells in pancreatic cancer. Surgery, 2002, 131: 135-138.
